OSIRIS THERAPEUTICS, INC.
DelistedCIK 1360886fmd_1HCE9BJF8MKFJ60KBVQF3Q69YJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Dec 31, 2018, 36 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 45 | 43 | 42 | 12 | – | – | – | – | 119 | 143 |
| Cost of revenue | – | 0 | 1 | 2 | 7 | 10 | 27 | 31 | 33 | 38 |
| Realized investment gains (losses) | 1 | 0 | 0 | – | – | – | (3) | (0) | (2) | (0) |
| Gross profit | – | 0 | 1 | 5 | 19 | 41 | 53 | 79 | 86 | 105 |
| Research and development | 63 | 24 | 4 | 4 | 4 | 3 | 5 | 6 | 4 | 7 |
| Selling, general and administrative | – | – | 7 | 5 | 16 | 44 | 66 | 76 | 84 | 87 |
| Total operating expenses | 72 | 30 | 12 | 11 | 21 | 48 | 86 | 83 | 88 | 95 |
| Operating income | (28) | 13 | (11) | (6) | (2) | (7) | (34) | (4) | (2) | 10 |
| Other non-operating income (expense) | – | – | – | 0 | 0 | (2) | (2) | 0 | (1) | 1 |
| Income before taxes | (26) | 13 | (11) | (6) | (2) | (9) | (35) | (4) | (3) | 11 |
| Income tax expense | (3) | 0 | (1) | (0) | (1) | 0 | 1 | 0 | (1) | (26) |
| Net income from continuing operations | (24) | 13 | (10) | (6) | (1) | (9) | (36) | (4) | (1) | 37 |
| Net income | – | – | – | – | – | – | (36) | (4) | 9 | 37 |
| Net income to common shareholders | 15 | 13 | 15 | (12) | 42 | (10) | (36) | (4) | 9 | 37 |